IFNG and plasma cell myeloma: A clinical study in multiple myeloma patients showed that patients with higher expression of IFNγ, IFNγ-inducible genes, and Th1-associated markers achieved better clinical response to ipilimumab, which suggests that an activated immune microenvironment can be used as a biomarker of response (Maleki Vareki et al., 2017).